Evidence map›Paper›PMID 39696364›Full record

ArticleJournal of hematology & oncology2024

myCAF-derived exosomal PWAR6 accelerates CRC liver metastasis via altering glutamine availability and NK cell function in the tumor microenvironment.

Hongsheng Fang, Weixing Dai, Ruiqi Gu, Yanbo Zhang, Jin Li, Wenqin Luo, Shanyou Tong, Lingyu Han, Yichao Wang, Chengyao Jiang and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Journal of hematology & oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Hongsheng Fang *Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Weixing Dai *Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Ruiqi Gu *Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yanbo Zhang *Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Jin LiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Wenqin LuoDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Shanyou TongDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Lingyu HanDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yichao WangDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Chengyao JiangDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Xue WangDepartment of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. wangxuefghc@163.com.
Renjie WangDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. wangbladejay@sina.com.
Guoxiang CaiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. gxcaifuscc@163.com.

Funding

National Natural Science Foundation of China 82003317National Natural Science Foundation of China 8217112384National Natural Science Foundation of China 82303318
6 · The paper itself

Abstract

backgroundLiver metastasis from colorectal cancer (CRC) is a major clinical challenge that severely affects patient survival. myofibroblastic cancer-associated fibroblasts (myCAFs) are a major component of the CRC tumor microenvironment, where they contribute to tumor progression and metastasis through exosomes.

methodsSingle-cell analysis highlighted a notable increase in myCAFs in colorectal cancer liver metastases (CRLM). Exosomal sequencing identified PWAR6 as the most significantly elevated lncRNA in these metastatic tissues. In vivo and in vitro assays confirmed PWAR6's roles in CRC cell stemness, migration, and glutamine uptake. RNA pulldown, RIP, and Co-IP assays investigated the molecular mechanisms of the PWAR6/NRF2/SLC38A2 signaling axis in CRC progression, flow cytometry was used to assess NK cell activity and cytotoxicity.

resultsClinically, higher PWAR6 expression levels are strongly associated with increased

conclusionmyCAFs derived exosomes PWAR6 represents a pivotal marker for CRC liver metastasis, and its targeted inhibition with ASO-PWAR6, in combination with FAPI treatment, effectively curtails metastasis in preclinical models, offering promising therapeutic potential for clinical management.

Indexed as

Colorectal NeoplasmsExosomesGlutamineKiller Cells, NaturalLiver NeoplasmsTumor MicroenvironmentAnimalsCancer-Associated FibroblastsCell Line, TumorHumansMaleMiceRNA, Long NoncodingGlutamineRNA, Long Noncoding

Identifiers

PMID39696364
PMCPMC11657131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.